| 1 | 11431348 | Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. | Cancer Res | 2001 Jul 1 |
4 |
| 2 | 11478941 | Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. | FEBS Lett | 2001 Jul 27 |
7 |
| 3 | 11560954 | Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. | J Clin Invest | 2001 Sep |
1 |
| 4 | 11728381 | Suppression of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated CYP1A1 and CYP1B1 induction by 12-O-tetradecanoylphorbol-13-acetate: role of transforming growth factor beta and mitogen-activated protein kinases. | Biochem Pharmacol | 2001 Dec 1 |
2 |
| 5 | 11782377 | Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. | Cancer Res | 2002 Jan 1 |
13 |
| 6 | 11964319 | Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. | Blood | 2002 May 1 |
3 |
| 7 | 12069688 | Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1. | Biochem J | 2002 Sep 1 |
2 |
| 8 | 12210141 | MEK inhibitor U0126 interferes with immunofluorescence analysis of apoptotic cell death. | Cytometry | 2002 Aug 1 |
1 |
| 9 | 12727228 | Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/-9/-14 and CD44. | Biochem Biophys Res Commun | 2003 May 16 |
7 |
| 10 | 12814546 | Negative feedback regulation of FGF signaling levels by Pyst1/MKP3 in chick embryos. | Curr Biol | 2003 Jun 17 |
1 |
| 11 | 12907754 | Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways. | Mol Endocrinol | 2003 Nov |
3 |
| 12 | 12963734 | Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro. | J Biol Chem | 2003 Nov 21 |
3 |
| 13 | 14566055 | Extracellular signal-regulated kinase 2 is necessary for mesoderm differentiation. | Proc Natl Acad Sci U S A | 2003 Oct 28 |
3 |
| 14 | 14613031 | CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). | Semin Oncol | 2003 Oct |
8 |
| 15 | 14645670 | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL. | Mol Pharmacol | 2003 Dec |
6 |
| 16 | 14737074 | Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. | Leukemia | 2004 Mar |
7 |
| 17 | 14741046 | Stress- and mitogen-induced phosphorylation of the synapse-associated protein SAP90/PSD-95 by activation of SAPK3/p38gamma and ERK1/ERK2. | Biochem J | 2004 May 15 |
1 |
| 18 | 15031205 | Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells. | Blood | 2004 Jul 15 |
1 |
| 19 | 15109307 | Analysis of the ERK1,2 transcriptome in mammary epithelial cells. | Biochem J | 2004 Aug 1 |
1 |
| 20 | 15171791 | Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure. | BMC Cancer | 2004 Jun 1 |
8 |
| 21 | 15180527 | MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. | Curr Pharm Des | 2004 |
1 |
| 22 | 15286700 | Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells. | Oncogene | 2004 Sep 23 |
4 |
| 23 | 15299081 | Inhibition of constitutively activated nuclear factor-kappaB radiosensitizes human melanoma cells. | Mol Cancer Ther | 2004 Aug |
2 |
| 24 | 15381709 | Characterization of the MEK5-ERK5 module in human neutrophils and its relationship to ERK1/ERK2 in the chemotactic response. | J Biol Chem | 2004 Nov 26 |
5 |
| 25 | 15483017 | Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. | J Clin Oncol | 2004 Nov 15 |
1 |
| 26 | 15497695 | In vitro and in vivo metabolism of the anti-cancer agent CI-1040, a MEK inhibitor, in rat, monkey, and human. | Pharm Res | 2004 Sep |
2 |
| 27 | 15805287 | Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. | Cancer Res | 2005 Apr 1 |
2 |
| 28 | 15967111 | A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. | Neoplasia | 2005 Apr |
6 |
| 29 | 16007158 | ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells. | Oncogene | 2005 Oct 13 |
1 |
| 30 | 16009947 | Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. | J Clin Oncol | 2005 Aug 10 |
4 |
| 31 | 16015388 | Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. | Leukemia | 2005 Sep |
6 |
| 32 | 16239399 | The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines. | J Pharmacol Exp Ther | 2006 Jan |
1 |
| 33 | 16247486 | LIGHT induces differentiation of mouse embryonic stem cells associated with activation of ERK5. | Oncogene | 2006 Jan 19 |
3 |
| 34 | 16261397 | Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. | Breast Cancer Res Treat | 2006 Mar |
4 |
| 35 | 16267021 | Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells. | Cancer Res | 2005 Nov 1 |
4 |
| 36 | 16319524 | Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. | Cancer Biol Ther | 2005 Nov |
1 |
| 37 | 16467208 | MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. | Blood | 2006 Jun 1 |
1 |
| 38 | 16609040 | Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate. | Clin Cancer Res | 2006 Apr 1 |
7 |
| 39 | 16641154 | Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. | J Am Soc Nephrol | 2006 Jun |
3 |
| 40 | 16848763 | Phosphorylation of the ARE-binding protein DAZAP1 by ERK2 induces its dissociation from DAZ. | Biochem J | 2006 Oct 15 |
4 |
| 41 | 16891476 | Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration. | Mol Cancer Ther | 2006 Jul |
1 |
| 42 | 16952276 | Lovastatin inhibits the extracellular-signal-regulated kinase pathway in immortalized rat brain neuroblasts. | Biochem J | 2007 Jan 1 |
2 |
| 43 | 16957420 | MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo. | Cancer Biol Ther | 2006 Oct |
1 |
| 44 | 17077328 | MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. | Blood | 2007 Mar 1 |
1 |
| 45 | 17213817 | Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1. | Oncogene | 2007 Jun 7 |
5 |
| 46 | 17218385 | MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. | Blood | 2007 May 1 |
6 |
| 47 | 17332937 | Inhibition of the MAP kinase activity suppresses estrogen-induced breast tumor growth both in vitro and in vivo. | Int J Oncol | 2007 Apr |
2 |
| 48 | 17382186 | Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells. | Urology | 2007 Mar |
1 |
| 49 | 17510423 | Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. | Cancer Res | 2007 May 15 |
3 |
| 50 | 17692050 | Targeting of FAK Ser910 by ERK5 and PP1delta in non-stimulated and phorbol ester-stimulated cells. | Biochem J | 2007 Nov 15 |
2 |